Sub-clinical glutamate receptor antagonist combinations prevent progressive demyelination.
Mitchener, V.; Bulman, C.; Mellor, A.; Bhatt, N.; Alghamdi, B.; Nash, J.; Morgan, D.; Proctor, R.; Smith, N.; Newman, A.; Nwabiakam, V.; Stone, G.; Woznica, W.; Harper, G.; PEREZ, A. L.; PEREZ, F.; Valentino, M.; MATUTE, C.; Fern, R.
Show abstract
Multiple sclerosis (MS) affects almost 3 million people globally who suffer demyelination as a series of relapses and remissions that tend towards progressive deterioration over time. The proximate cause is auto-immune attack by the adaptive immune system; therapies directed against this are effective during the relapsing-remitting phase but are less effective or ineffective during progression where other injury mechanisms may be significant. LPS- and cuprizone-induced experimental demyelination share features of progressive demyelination in MS but the underlying mechanisms are not well understood. We show here that these demyelination models can be reproduced ex vivo using short protocols, revealing that combined antagonism of two types of glutamate receptor, NMDA and AMPA, using clinically approved antagonists at sub-clinical doses, can protect against these forms of demyelination. Combined low dose therapy was subsequently shown to be effective in vivo against dietary cuprizone and experimental autoimmune-encephalomyelitis (EAE) models of demyelination and, in particular, protected the smaller myelinated axons that are the main substrate of the function loss in progressive MS.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Neuro-immunology in a mouse model of anti-NMDAR encephalitis and assessment of treatment approaches 95%
- Lymphotoxin-alpha expression in the meninges causes lymphoid tissue formation and neurodegeneration 95%
- Activation of XBP1s attenuates disease severity in models of proteotoxic Charcot-Marie-Tooth type 1B 95%
Similar papers in this journal
- Reduction in CD11c+ microglia correlates with clinical progression in chronic experimental autoimmune demyelination 96%
- Fibrotic scar after experimental autoimmune encephalomyelitis inhibits oligodendrocyte differentiation 95%
- Circulating Myeloid-Derived Suppressor Cell load and disease severity are associated to an enhanced oligodendroglial production in a murine model of multiple sclerosis 94%
Similar papers in this journal
- TPPB modulates PKC activity to attenuate neuroinflammation and ameliorate experimental multiple sclerosis 96%
- Reversible loss of Hippocampal Function in a Mouse Model of Demyelination/Remyelination 93%
- Single-cell analysis of antiviral neuroinflammatory responses in the mouse dorsal raphe nucleus 93%
Similar papers in this journal
- Autoimmune inflammation triggers aberrant astrocytic calcium signaling to impair synaptic plasticity 96%
- The effects of P2Y12 loss on microglial gene expression, dynamics, and injury response in the cerebellum and cerebral cortex. 95%
- Oral vancomycin treatment alters levels of indole derivatives and secondary bile acids modulating the expression of mTOR pathway genes in astrocytes during EAE 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.